Fujisawa Tetsunori, Igeta Katsuhiro, Odake Shinjiro, Morita Yasuo, Yasuda Junko, Morikawa Tadanori
Research Institute, Daiichi Fine Chemical Co., Ltd., 530 Chokeiji, Takaoka, Toyama 933-8511, Japan.
Bioorg Med Chem. 2002 Aug;10(8):2569-81. doi: 10.1016/s0968-0896(02)00109-8.
A new series of succinate-based dual inhibitors against matrix metalloproteinases (MMPs) and tumor necrosis factor alpha converting enzyme (TACE) possessing highly-water solubility was designed, synthesized, and evaluated for enzyme inhibition. Incorporating of acidic or basic functional groups at the P(2)' position afforded sufficient water solubility without significant loss of inhibitory potencies. Compound 18e, which had a guanidino group at the P(2)' position as the basic functional group, exhibited broad inhibition against target enzymes for a relatively long period in rat plasma (beta t(1/2); 2.0h) after sc administration when compared with compounds possessing acidic functional groups (18a and 18b). Consequently, the representative compound 18e together with compound 18b, Marimastat and Trocade were evaluated in the rat adjuvant-induced arthritis model, a model of chronic cartilage destruction. It is concluded that the newly synthesized highly water-soluble compound 18e showed significant activity in suppressing hindpaw swelling and the bone destruction with a minimal administration period (days 3-7).
设计、合成并评估了一系列新型的基于琥珀酸的双抑制剂,它们对基质金属蛋白酶(MMPs)和肿瘤坏死因子α转换酶(TACE)具有高水溶性,并进行了酶抑制研究。在P(2)' 位引入酸性或碱性官能团可提供足够的水溶性,而不会显著损失抑制活性。与具有酸性官能团的化合物(18a和18b)相比,在P(2)' 位具有胍基作为碱性官能团的化合物18e在皮下给药后在大鼠血浆中对靶酶表现出较长时间的广泛抑制作用(β t(1/2);2.0小时)。因此,在大鼠佐剂性关节炎模型(一种慢性软骨破坏模型)中评估了代表性化合物18e以及化合物18b、马立马司他和曲卡替尼。结果表明,新合成的高水溶性化合物18e在最短给药期(第3 - 7天)内对抑制后爪肿胀和骨质破坏具有显著活性。